Mithra Submits Myring™ for European Marketing Approval

  • Myring™ regulatory approvals in Europe and the US expected in 2018
  • Regulatory submission follows recent European GMP approval for Myring™ production at Mithra CDMO

Liège, Belgium, 17 July 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, announces that it has filed Myring™ for marketing approval in Europe. Myring™ is Mithra’s version of Nuvaring™, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA). The global market for Nuvaring™ amounts to approximately USD 960 million, with over 75% of sales in the US.